Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 372,064,544
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.70
  • Price/Sales 4.88
  • Price/Cash Flow 14.55
  • Price/Book 5.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.95
  • Number of Estimates 7
  • High Estimate 1.97
  • Low Estimate 1.93
  • Prior Year 1.74
  • Growth Rate Est. (year over year) +12.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
132.23 +4.94%
on 10/12/18
142.50 -2.62%
on 09/24/18
-4.12 (-2.88%)
since 09/21/18
3-Month
127.15 +9.13%
on 07/24/18
143.13 -3.05%
on 09/21/18
+12.13 (+9.58%)
since 07/23/18
52-Week
118.62 +16.98%
on 05/29/18
148.32 -6.45%
on 01/17/18
-4.86 (-3.38%)
since 10/23/17

Most Recent Stories

More News
Johnson & Johnson Vision Supports Patients, Ophthalmology Community Through New Products, Data, Educational Opportunities, and Charitable Giving at the 2018 AAO Annual Meeting

Johnson & Johnson Vision, a broad-based global leader in vision, will showcase the company's leadership in eye health, innovation and caring and giving at the 2018 American Academy of Ophthalmology's Annual...

JNJ : 138.91 (+0.17%)
Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC

The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.

MRK : 72.25 (-0.44%)
JNJ : 138.91 (+0.17%)
RHHBY : 30.7700 (+0.20%)
BMY : 51.00 (+0.24%)
Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines

Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.

JNJ : 138.91 (+0.17%)
ABBV : 83.04 (-1.46%)
RHHBY : 30.7700 (+0.20%)
BIIB : 320.31 (+1.51%)
Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT

Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.

SRPT : 134.86 (+1.74%)
JNJ : 138.91 (+0.17%)
VRTX : 176.45 (-0.54%)
ECYT : 23.54 (+0.09%)
NVS : 87.84 (+0.85%)
ALXN : 124.01 (+0.07%)
New Phase 2 Data Show Stelara® (Ustekinumab) Sustained Improvement In Disease Activity In Adults With Systemic Lupus Erythematosus Through One Year

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the continuation of a randomized, placebo-controlled Phase 2 study investigating STELARA® (ustekinumab) in the treatment...

JNJ : 138.91 (+0.17%)
Johnson & Johnson (JNJ) Stock Moves -0.27%: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $138.68, marking a -0.27% move from the previous day.

JNJ : 138.91 (+0.17%)
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?

We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.

JNJ : 138.91 (+0.17%)
MRK : 72.25 (-0.44%)
NVS : 87.84 (+0.85%)
RHHBY : 30.7700 (+0.20%)
ALKS : 40.27 (+3.63%)
BIIB : 320.31 (+1.51%)
The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet

The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet

NFLX : 334.20 (+1.41%)
MSFT : 108.52 (-1.01%)
GOOGL : 1,114.38 (+0.27%)
JNJ : 138.91 (+0.17%)
AMZN : 1,771.86 (-0.97%)
Upcoming Tech Earnings to Watch: MSFT, AMZN, GOOGL

More major tech reports will begin pouring in next week, and Wall Street will be hoping for strength from the sector's leaders. Here's a close look at a few of the major tech earnings reports due out in...

NFLX : 334.20 (+1.41%)
MSFT : 108.52 (-1.01%)
GOOGL : 1,114.38 (+0.27%)
JNJ : 138.91 (+0.17%)
AMZN : 1,771.86 (-0.97%)
Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical trial demonstrating that stably maintained rates of skin...

JNJ : 138.91 (+0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 139.81
1st Resistance Point 139.25
Last Price 138.95
1st Support Level 138.13
2nd Support Level 137.57

See More

52-Week High 148.32
Last Price 138.95
Fibonacci 61.8% 136.97
Fibonacci 50% 133.47
Fibonacci 38.2% 129.97
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar